Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
about
Endobronchial ultrasound elastography.Ultrasound techniques in the evaluation of the mediastinum, part 2: mediastinal lymph node anatomy and diagnostic reach of ultrasound techniques, clinical work up of neoplastic and inflammatory mediastinal lymphadenopathy using ultrasound techniquesUltrasound techniques in the evaluation of the mediastinum, part I: endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS) and transcutaneous mediastinal ultrasound (TMUS), introduction into ultrasound techniquesCombining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancerMeta-analysis of intentional sublobar resections versus lobectomy for early stage non-small cell lung cancerThe Role of PET/CT Molecular Imaging in the Diagnosis of Recurrence and Surveillance of Patients Treated for Non-Small Cell Lung CancerProblems of variable biomarker evaluation in stratified medicine research--A case study of ERCC1 in non-small-cell lung cancerA critical review of recent developments in radiotherapy for non-small cell lung cancerInter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair researchClinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer.Contrast-enhanced endobronchial ultrasound: Potential value of a new method.Nomograms for predicting recurrence and survival of invasive pathological stage IA non-small cell lung cancer treated by video assisted thoracoscopic surgery lobectomy.Adjuvant or neoadjuvant chemotherapy for NSCLC.HOXA5 and p53 cooperate to suppress lung cancer cell invasion and serve as good prognostic factors in non-small cell lung cancer.Experience improves the performance of endobronchial ultrasound-guided transbronchial biopsy for peripheral pulmonary lesions: A learning curve at a medical centreDownregulation of Mitochondrial Single Stranded DNA Binding Protein (SSBP1) Induces Mitochondrial Dysfunction and Increases the Radiosensitivity in Non-Small Cell Lung Cancer Cells.Simultaneous overactivation of Wnt/β-catenin and TGFβ signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC.18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic ResponsePredictors of imaging surveillance for surgically treated early-stage lung cancer.Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer.Communicating cancer treatment information using the Web: utilizing the patient's perspective in website developmentCost and effectiveness of video-assisted thoracoscopic surgery for clinical stage I non-small cell lung cancer: a population-based analysisFollow-up or Surveillance (18)F-FDG PET/CT and Survival Outcome in Lung Cancer Patients.A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer.SBRT in operable early stage lung cancer patients.Pre-operative chemotherapy for non-small cell lung carcinomaErythropoietin improves the accumulation and therapeutic effects of carboplatin by enhancing tumor vascularization and perfusionMulticenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study)The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients.Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study.Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinomaDoes early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer?Causes of death and subsequent treatment after initial radical or palliative therapy of stage III non-small-cell lung cancer.LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspectiveConsistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake timesAutophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway.Reasons for palliative treatments in stage III non-small-cell lung cancer: what contribution is made by time-dependent changes in tumour or patient status?Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.
P2860
Q26738484-B84EF622-0E3F-4D3E-8248-1E37E4D578CBQ26775697-AFC3F25D-5D17-40BD-8D09-E1EA7F4A1527Q26778702-B4754939-F64F-4D17-A7EF-0BC8394EE930Q26852202-9604226C-58E1-4424-AD9A-5CD875E54E3AQ27002509-0798AFEF-B4E7-4206-8D6B-95317A88A706Q27003464-470B0DC2-2AD2-42C9-90DD-839755E04DC9Q28066013-4AE6C712-C12D-4E8E-9C39-CDF5F3C33206Q28069810-58A65D9F-3EAE-47E4-BDB0-6708E87433FBQ28079625-DED1F095-A0D8-4B22-8D5A-B1AF53FE31AFQ28388726-8BC64895-3E66-46AE-AA28-5F2A7CDF3D80Q30250349-B8B347EB-3B49-4F7C-AC21-28B8A65C0AB3Q30361965-82A57B21-8A2C-4543-BC59-93EA82BA851DQ33639243-1682F8B9-4432-4EAF-95C3-0C610DFF194BQ33658228-931ED284-0AFE-4BEE-B7ED-386F4218D8FDQ33702367-5CF14835-3A91-441C-8B86-C4EBA49CFA52Q33817481-4A017B8E-EB17-478A-BAB3-89B2E2550063Q33820859-6F9A5FEC-A8F8-410F-95F9-5D304F71498DQ33827178-94DE7AE1-38C1-4035-ABFF-195E1C592D69Q33904549-0DF9E90F-579A-42DC-A966-BA2E302DECFFQ34633138-389A6B36-0C51-40A2-B6EE-EB5D6FF323F8Q34672375-8B4A2E6A-ACA1-49E8-B5D9-01E8C72DA77AQ34740086-4AF7C55D-24DE-4BBB-88E9-DE3AD4A56DA6Q34814512-56BE6050-A3F8-457A-BD18-8ED2815506A9Q35072593-0299A5F0-47B5-42CF-AEB8-57F6C67AB255Q35168112-F0ABA725-F742-4743-8634-48EB05554148Q35200592-863E488A-449F-4429-9607-A7C6092CB41DQ35200636-5112A4C7-A813-403D-894A-760B23BD201EQ35633372-F2ADF828-3F7A-4938-A639-0206BDAA6236Q35644940-03329230-DC37-425D-B7CB-3DA4B484060AQ35677914-2B58D915-F041-442B-B259-C656358538EEQ35739745-499A7D36-8E6A-4896-8AA8-2DF9F15BC551Q35870182-B789B272-3A51-47EF-93D3-EF4907C7EB13Q35940727-0B7E3C6F-A058-41EF-9834-98F526BEB8C4Q36100808-825AF676-EF8B-4EC6-9222-CCA8927A3A68Q36169818-A3286407-5B4C-432F-A3DC-D135F06C942DQ36235727-BEE6A846-506C-4676-98A7-89794481FE55Q36304366-503055A7-0560-4B61-808B-E3DBE7216F9BQ36390671-B1AC8AD5-3C58-4833-934F-2F2C7C562242Q36394587-6154D0D4-CC62-4D50-AB53-770E2C14F1A4Q36545005-E57646FD-E16B-4563-BEF4-DE695BF99218
P2860
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Early and locally advanced non ...... osis, treatment and follow-up.
@en
Early and locally advanced non ...... osis, treatment and follow-up.
@nl
type
label
Early and locally advanced non ...... osis, treatment and follow-up.
@en
Early and locally advanced non ...... osis, treatment and follow-up.
@nl
prefLabel
Early and locally advanced non ...... osis, treatment and follow-up.
@en
Early and locally advanced non ...... osis, treatment and follow-up.
@nl
P2093
P2860
P50
P356
P1433
P1476
Early and locally advanced non ...... nosis, treatment and follow-up
@en
P2093
D De Ruysscher
ESMO Guidelines Working Group
J Vansteenkiste
W E E Eberhardt
P2860
P304
P356
10.1093/ANNONC/MDT241
P478
24 Suppl 6
P577
2013-07-16T00:00:00Z